NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Axiom Therapeutics

Axiom Therapeutics

Private
LondonHealthcare & Life Scienceshttps://axiom-therapeutics.com/

Last Round

Seed

Mar 11, 2025

Company Overview

Axiom Therapeutics is a biotechnology company that develops a computational platform using machine learning and physics simulations to design covalent drugs for undruggable targets.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoverytechbiocovalent drugscomputational drug designcovalent inhibitorsAI drug discoveryin silico drug discoveryphysics-based simulationundruggable targetsbiotechsmall molecule designoncologyneurodegenerationimmunologydrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axiom Therapeutics Comparables

Compare Axiom Therapeutics with similar companies based on industry and business-model similarity.

Axiom Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kuano
88%
COHEAD Therapeutics
86%
Aqemia
81%

Axiom Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 11, 2025
AcceleratorApr 1, 2024
GrantSep 1, 2022

Key People

Founding team and executive leadership

Chris Haggard

Co-Founder & CTO

Founding Team

Ryan Geiser

CEO & Co-Founder

Founding Team

Axiom Therapeutics Investors

Notable investors and investment history

Axiom Therapeutics investors
InvestorRounds
Verve VenturesSeed
Samos InvestmentsSeed
Innovate UKGrant
Cambridge EnterpriseSeed
Entrepreneurs FirstAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 6, 2026

    Monthly visitors increased 130% MoM, reaching 450.

  • May 12, 2025

    Grew 200% QoQ from 2 to 6 employees.

Axiom Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Axiom Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axiom Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range8
Year Founded2024
Last FundingMar 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.